Continuing its plan to divest ~$10B in non-core assets aimed at reducing its leverage, Takeda Pharmaceutical Company (TAK +1.5%) has agreed to sell a portfolio of over-the-counter and prescription products sold in Latin America to Brazil’s Hypera S.A. for $825M.
The line-up of ~18 medicines generated ~$215M in sales in fiscal 2018.
The transaction, the company’s fifth divestment over the past 12 months, should close in H2.
https://seekingalpha.com/news/3547523-takeda-to-divest-certain-latin-american-assets-for-825m
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.